Percutaneous coronary intervention (PCI) is a minimally invasive technique used to reopen narrowed or blocked coronary arteries caused by atherosclerosis. In which stent is implanted to reopen arteries, but after some time, it gets narrowed again, called restenosis, which is a reduction in lumen diameter after PCI. Drug-eluting stents (DES) were developed to specifically address the problems of restenosis encountered with BMS ISR. Drug-eluting stent was found to be better than other types of stents. These stents are coated with drugs like paclitaxel, sirolimus, zotarolimus, or everolimus. Primarily, PLGA or PLA polymers are used to increase the release of the drug for a longer duration. Most drug-eluting stent manufacturers use PLGA or PLA to load the medicine and coating of the stent. The required course of release of sirolimus or everolimus for transplant success will be 90 days or more. However, the PLGA-coated Genex stents loaded with sirolimus provided the release of 30 days (Purple Micro Port Pvt. Ltd.). Chitosan is known for its extended release of drugs. Further, the drug sirolimus was analyzed to have 14 hydrogen bond acceptors. Thus, chitosan rich in hydrogen bond donors will be used for the modification. Moreover, the sulphonamide-containing linkers are reported to be pH sensitive (pH 7.2-7.4). Thus, a novel modified polymer contains PLGA and chitosan linked with a pH-sensitive sulphonamide linkage. The novel polymer rich in Hydrogen bond donors will improve drug loading and release. Thus, the pH sensitivity and enhanced drug loading may increase the release from 30 to 90 days.